Shares of Fortress Biotech (NASDAQ:FBIO) have received a consensus rating of “Buy” from the eight brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $10.75.
Several brokerages have recently issued reports on FBIO. ValuEngine raised Fortress Biotech from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Zacks Investment Research cut Fortress Biotech from a “hold” rating to a “sell” rating in a report on Monday, June 11th. B. Riley began coverage on Fortress Biotech in a report on Wednesday, February 28th. They set a “buy” rating and a $10.00 price objective on the stock. JMP Securities set a $11.00 price objective on Fortress Biotech and gave the stock a “buy” rating in a report on Monday, May 21st. Finally, HC Wainwright set a $11.00 price objective on Fortress Biotech and gave the stock a “buy” rating in a report on Tuesday, March 27th.
Top 5 Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)
- [By Cory Renauer]
What’s behind these dramatic gains? Read on to find out.
Company Gain in H1 2018 Market Cap
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL) 205% $3.99 billion
Data source: YCharts.
- [By Money Morning Staff Reports]
But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…
Penny Stock Current Share Price Law Month’s Gain
Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
Transenterix Inc. (NYSE: TRXC) $3.46 77.84%
While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.
- [By Lisa Levin] Gainers
Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.
Check out these big penny stock gainers and losers
Top 5 Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)
- [By Keith Speights]
Three biotech stocks that achieved this feat this week areNightstar Therapeutics (NASDAQ:NITE),Arbutus Biopharma (NASDAQ:ABUS), andBiogen (NASDAQ:BIIB). What caused these stocks to soar, and are they smart picks to buy now? Here’s what you need to know.
- [By Chris Lange]
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen Inc. (NASDAQ: BIIB). Through this partnership, these companies are planning to tackle and develop novel antisense drug candidates for a broad range of neurological diseases.
- [By Keith Speights]
Ionis has solid revenue coming in the door thanks to Spinraza. Biogen (NASDAQ:BIIB) markets the spinal muscular atrophy (SMA) drug, but Ionis receives royalties on all sales. In Q1, those royalties totaled $41 million, up from $5 million in the prior-year period.
Top 5 Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)
- [By Joseph Griffin]
South Dakota Investment Council lowered its stake in Amgen (NASDAQ:AMGN) by 59.4% during the 1st quarter, HoldingsChannel reports. The fund owned 77,041 shares of the medical research company’s stock after selling 112,589 shares during the quarter. South Dakota Investment Council’s holdings in Amgen were worth $13,134,000 at the end of the most recent quarter.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.72 million shares from the previous level of 9.62 million. Shares were last seen at $184.61 in a 52-week trading range of $161.13 to $201.23.
- [By Ethan Ryder]
Wayne Hummer Investments L.L.C. trimmed its position in shares of Amgen (NASDAQ:AMGN) by 11.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,311 shares of the medical research company’s stock after selling 303 shares during the period. Wayne Hummer Investments L.L.C.’s holdings in Amgen were worth $394,000 at the end of the most recent quarter.
- [By ]
Booker’s report took on other companies as well. Pfizer (PFE) , Gilead Sciences (GILD) , AbbVie (ABBV) , Amgen (AMGN) , Bristol-Myers Squibb (BMY) Eli Lilly & Co. (LLY) , and Mylan NV (MYL) are cited for everything from raising drug prices, to stock buybacks and putting shareholder interest before that of the public.
Top 5 Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Brian Orelli]
The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.
- [By Keith Speights]
It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.
- [By Sean Williams, Chuck Saletta, and Brian Feroldi]
So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).